While CF treatments drive current growth, Vertex's pipeline holds significant potential for future expansion. The company is preparing for two key drug approvals in January 2025: suzetrigine for ...

Yee is optimistic about Vertex’s future, especially with three product launches expected in 2025 and their robust pipeline progress, which includes promising developments in late-stage projects ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs and potential product launches are on the horizon ...

“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will ... disease areas of focus, R&D pipeline, and geographies to continue to deliver long-term value to both patients ...

Vertex reports Q4 earnings Monday, with Wall Street expecting $4.03 EPS and $2.78 billion revenue. Strong technicals support VRTX stock, but selling pressure and pipeline execution remain key ...

This expansion of the addressable market underscores the long-term sustainability of Vertex's CF business. Vertex's pipeline is diverse and promising, with several potential catalysts on the horizon.

Vertex has attracted interest from Wall Street for its ambitious drug pipeline that involves winning FDA approval for multiple drugs across several forms of chronic pain, which generally ...

While CF remains Vertex's primary revenue driver, the company is actively working to diversify its portfolio. Several key pipeline programs and potential product launches are on the horizon: 1.